Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: Ligand presentation using molecular rods

Stefania Ordanini, Norbert Varga, Vanessa Porkolab, Michel Thépaut, Laura Belvisi, Andrea Bertaglia, Alessandro Palmioli, Angela Berzi, Daria Trabattoni, Mario Clerici, Franck Fieschi, Anna Bernardi

Research output: Contribution to journalArticle

Abstract

DC-SIGN antagonists were designed combining one selective monovalent glycomimetic ligand with trivalent dendrons separated by a rigid core of controlled length. The design combines multiple multivalency effects to achieve inhibitors of HIV infection, which are active in nanomolar concentration.

Original languageEnglish
Pages (from-to)3816-3819
Number of pages4
JournalChemical Communications
Volume51
Issue number18
DOIs
Publication statusPublished - Mar 4 2015

    Fingerprint

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis
  • Ceramics and Composites
  • Electronic, Optical and Magnetic Materials
  • Surfaces, Coatings and Films
  • Materials Chemistry
  • Metals and Alloys
  • Medicine(all)

Cite this

Ordanini, S., Varga, N., Porkolab, V., Thépaut, M., Belvisi, L., Bertaglia, A., Palmioli, A., Berzi, A., Trabattoni, D., Clerici, M., Fieschi, F., & Bernardi, A. (2015). Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: Ligand presentation using molecular rods. Chemical Communications, 51(18), 3816-3819. https://doi.org/10.1039/c4cc09709b